HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical importance of discordance of hormone receptors and Her2/neu status after neoadjuvant chemotherapy in breast cancer.

AbstractPURPOSE:
The aim of this study was to compare the hormone receptors' (HR) and HER2/neu status between core needle biopsy (CNB) and residual tumor after surgery of breast cancer treated with neoadjuvant chemotherapy (NAC), and also to evaluate the impact of discordance and other clinicopathological factors on survival.
METHODS:
Oestrogen receptor (ER), progesterone receptor (PR) and HER2/neu status were evaluated by immunohistochemistry (IHC) on 90 CNBs of primary tumors and surgical specimens after NAC (study group); 53 patients without NAC served as control group, and discordance was compared between the two groups. The association between discordance of HR status after NAC and various other clinicopathological factors was tested with Spearman's test.
RESULTS:
Pathological complete response (PCR) was achieved in 10 (11.1%) patients after NAC. ER and PR changed significantly more in the study than in the control group. ER and PR discordance was detected in 10 (12.5%) and 17 (21.2%) patients in the NAC group and in 1 (1.8%) and 2 (3.7%) patients in the control group (p=0.04 and p=0.005, respectively). ER discordance was related with HER2/neu change. Furthermore, PR discordance correlated with CNB, ER and treatment response, while HER2/ neu discordance was associated with treatment response (p=0.05). ER discordance was found to be an independent prognostic factor for progression-free survival (PFS) (p=0.02).
CONCLUSION:
NAC might cause alterations in ER, PR or HER2//neu status in breast cancer, and they should be re-tested in the residual tumor after NAC to optimize adjuvant therapy.
AuthorsBala Basak Oven Ustaalioglu, Fugen Aker Vardar, Ahmet Bilici, Gunay Gurleyik, Burcak Erkol, Umut Kefeli, Mehmet Aliustaoglu
JournalJournal of B.U.ON. : official journal of the Balkan Union of Oncology (J BUON) 2014 Oct-Dec Vol. 19 Issue 4 Pg. 879-86 ISSN: 1107-0625 [Print] Cyprus
PMID25536590 (Publication Type: Journal Article)
Chemical References
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Receptor, ErbB-2
Topics
  • Breast Neoplasms (drug therapy)
  • Case-Control Studies
  • Disease-Free Survival
  • Humans
  • Neoadjuvant Therapy
  • Receptor, ErbB-2
  • Receptors, Estrogen
  • Receptors, Progesterone

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: